Cargando…
Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban
OBJECTIVE: This study assesses the mortality outcomes of non‐vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with venous thromboembolism (VTE) and atrial fibrillation (AF). METHODS: Medical records of cancer patients receiving NOACs for VTE or AF between January 1, 2011, and Dece...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525135/ https://www.ncbi.nlm.nih.gov/pubmed/34464520 http://dx.doi.org/10.1002/cam4.4241 |
_version_ | 1784585632211795968 |
---|---|
author | Lin, Yu‐Sheng Kuan, Feng‐Che Chao, Tze‐Fan Wu, Michael Chen, Shao‐Wei Chen, Mien‐Cheng Chung, Chang‐Ming Chu, Pao‐Hsien Lip, Gregory Y. H. Wu, Victor Chien‐Chia |
author_facet | Lin, Yu‐Sheng Kuan, Feng‐Che Chao, Tze‐Fan Wu, Michael Chen, Shao‐Wei Chen, Mien‐Cheng Chung, Chang‐Ming Chu, Pao‐Hsien Lip, Gregory Y. H. Wu, Victor Chien‐Chia |
author_sort | Lin, Yu‐Sheng |
collection | PubMed |
description | OBJECTIVE: This study assesses the mortality outcomes of non‐vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with venous thromboembolism (VTE) and atrial fibrillation (AF). METHODS: Medical records of cancer patients receiving NOACs for VTE or AF between January 1, 2011, and December 31, 2016, were retrieved from Taiwan's National Health Institute Research Database. NOACs were compared using the inverse probability of treatment weighting (IPTW) method. The primary outcome was cancer‐related death. Secondary outcomes were all‐cause mortality, major bleeding, and gastrointestinal (GI) bleeding. RESULTS: Among 202,754 patients who received anticoagulants, 3591 patients (dabigatran: 907; rivaroxaban: 2684) with active cancers were studied. Patients who received dabigatran were associated with lower risks of cancer‐related death at one year (HR = 0.71, 95% CI = 0.54–0.93) and at the end of follow‐ups (HR = 0.79, 95% CI = 0.64–0.98) compared with rivaroxaban. Patients who received dabigatran were also associated with lower risks of all‐cause mortality (HR = 0.81, 95% CI = 0.67–0.97), major bleeding (HR = 0.64, 95% CI = 0.47–0.88), and GI bleeding (HR = 0.57, 95% CI = 0.39–0.84) at the end of follow‐ups compared with rivaroxaban. CONCLUSION: Compared with rivaroxaban, the use of dabigatran may be associated with a lower risk of cancer‐related death and all‐cause mortality. |
format | Online Article Text |
id | pubmed-8525135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85251352021-10-26 Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban Lin, Yu‐Sheng Kuan, Feng‐Che Chao, Tze‐Fan Wu, Michael Chen, Shao‐Wei Chen, Mien‐Cheng Chung, Chang‐Ming Chu, Pao‐Hsien Lip, Gregory Y. H. Wu, Victor Chien‐Chia Cancer Med Clinical Cancer Researcher OBJECTIVE: This study assesses the mortality outcomes of non‐vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with venous thromboembolism (VTE) and atrial fibrillation (AF). METHODS: Medical records of cancer patients receiving NOACs for VTE or AF between January 1, 2011, and December 31, 2016, were retrieved from Taiwan's National Health Institute Research Database. NOACs were compared using the inverse probability of treatment weighting (IPTW) method. The primary outcome was cancer‐related death. Secondary outcomes were all‐cause mortality, major bleeding, and gastrointestinal (GI) bleeding. RESULTS: Among 202,754 patients who received anticoagulants, 3591 patients (dabigatran: 907; rivaroxaban: 2684) with active cancers were studied. Patients who received dabigatran were associated with lower risks of cancer‐related death at one year (HR = 0.71, 95% CI = 0.54–0.93) and at the end of follow‐ups (HR = 0.79, 95% CI = 0.64–0.98) compared with rivaroxaban. Patients who received dabigatran were also associated with lower risks of all‐cause mortality (HR = 0.81, 95% CI = 0.67–0.97), major bleeding (HR = 0.64, 95% CI = 0.47–0.88), and GI bleeding (HR = 0.57, 95% CI = 0.39–0.84) at the end of follow‐ups compared with rivaroxaban. CONCLUSION: Compared with rivaroxaban, the use of dabigatran may be associated with a lower risk of cancer‐related death and all‐cause mortality. John Wiley and Sons Inc. 2021-08-31 /pmc/articles/PMC8525135/ /pubmed/34464520 http://dx.doi.org/10.1002/cam4.4241 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Researcher Lin, Yu‐Sheng Kuan, Feng‐Che Chao, Tze‐Fan Wu, Michael Chen, Shao‐Wei Chen, Mien‐Cheng Chung, Chang‐Ming Chu, Pao‐Hsien Lip, Gregory Y. H. Wu, Victor Chien‐Chia Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title | Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title_full | Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title_fullStr | Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title_full_unstemmed | Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title_short | Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban |
title_sort | mortality associated with the use of non‐vitamin k antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban |
topic | Clinical Cancer Researcher |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525135/ https://www.ncbi.nlm.nih.gov/pubmed/34464520 http://dx.doi.org/10.1002/cam4.4241 |
work_keys_str_mv | AT linyusheng mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT kuanfengche mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT chaotzefan mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT wumichael mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT chenshaowei mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT chenmiencheng mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT chungchangming mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT chupaohsien mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT lipgregoryyh mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban AT wuvictorchienchia mortalityassociatedwiththeuseofnonvitaminkantagonistoralanticoagulantsincancerpatientsdabigatranversusrivaroxaban |